Last updated 4 days ago
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
1147 patients around the world
Available in Chile, United States, Brazil, Argentina, Puerto Rico
Bristol-Myers Squibb
1Research sites
1147Patients around the world
This study is for people with
Colorectal cancer
Colon cancer
Rectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologically confirmed recurrent or metastatic colorectal cancer (CRC) irrespective of prior treatment history with chemotherapy and/or targeted agents not amenable to surgery (Applicable only during Part 1 enrollment of the study)Histologically confirmed recurrent or metastatic CRC with no prior treatment history with chemotherapy and/or targeted agents for metastatic disease and not amenable to surgery (Applicable during Part 2 enrollment of the study)Known tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status per local standard of practiceEastern cooperative oncology group (ECOG) performance status lower than or equal to 1
- An active, known or suspected autoimmune diseaseHistory of interstitial lung disease or pneumonitisKnown history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Sites
Exelsus - Oncología Clínica - Tucumán
StudyCheckMate 8HW
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Colon cancerRectal cancerColorectal cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04008030
